Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

November 11, 2024

Study Completion Date

November 11, 2024

Conditions

Colitis, Ulcerative

Interventions

DRUG

Tulisokibart

SC Injection or IV Infusion

DRUG

Placebo

Tulisokibart-matched Placebo SC Injection or IV Infusion

Trial Locations (1)

Peking University Third Hospital (Site 0001), Beijing

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06829225 - Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) | Biotech Hunter | Biotech Hunter